Nature Communications (Dec 2017)
Immune stealth-driven O2 serotype prevalence and potential for therapeutic antibodies against multidrug resistant Klebsiella pneumoniae
- Meghan E. Pennini,
- Anna De Marco,
- Mark Pelletier,
- Jessica Bonnell,
- Romana Cvitkovic,
- Martina Beltramello,
- Elisabetta Cameroni,
- Siro Bianchi,
- Fabrizia Zatta,
- Wei Zhao,
- Xiaodong Xiao,
- Maria M. Camara,
- Antonio DiGiandomenico,
- Elena Semenova,
- Antonio Lanzavecchia,
- Paul Warrener,
- JoAnn Suzich,
- Qun Wang,
- Davide Corti,
- C. Kendall Stover
Affiliations
- Meghan E. Pennini
- MedImmune
- Anna De Marco
- Humabs BioMed SA, a subsidiary of Vir Biotechnology, Inc.
- Mark Pelletier
- MedImmune
- Jessica Bonnell
- MedImmune
- Romana Cvitkovic
- MedImmune
- Martina Beltramello
- Humabs BioMed SA, a subsidiary of Vir Biotechnology, Inc.
- Elisabetta Cameroni
- Humabs BioMed SA, a subsidiary of Vir Biotechnology, Inc.
- Siro Bianchi
- Humabs BioMed SA, a subsidiary of Vir Biotechnology, Inc.
- Fabrizia Zatta
- Humabs BioMed SA, a subsidiary of Vir Biotechnology, Inc.
- Wei Zhao
- MedImmune
- Xiaodong Xiao
- MedImmune
- Maria M. Camara
- MedImmune
- Antonio DiGiandomenico
- MedImmune
- Elena Semenova
- MedImmune
- Antonio Lanzavecchia
- Institute for Research in Biomedicine, Università della Svizzera Italliana
- Paul Warrener
- MedImmune
- JoAnn Suzich
- MedImmune
- Qun Wang
- MedImmune
- Davide Corti
- Humabs BioMed SA, a subsidiary of Vir Biotechnology, Inc.
- C. Kendall Stover
- MedImmune
- DOI
- https://doi.org/10.1038/s41467-017-02223-7
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 12
Abstract
Therapeutics to combat multidrug-resistant bacteria such as Klebsiella pneumoniae are needed. Here the authors show immune evasion drives lipopolysaccharide O2 serotype expansion in multidrug-resistant isolates, and anti-O-antigen human monoclonal antibodies synergize with antibiotics to protect mice from infection.
